Study design and participants for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- 108 Participants between the ages of 18 and 60 were used in the study. All participants do not have prior SARS-CoV-2 infection. Other factors that can cause ineligibility include having a history of mental illness and seizures, allergies to ingredients in the vaccine, received blood products within the past four months, and received research medicine and vaccines within the past four months.
- The dosage-escalation method consists of participants being placed into three different group, each group receiving a different dosage of the vaccine. This includes a low dose, medium dose, or high dose group, each with 5 × 10^10, 1 × 10^11, and 1·5 × 10^11 viral particles respectively.
0
1
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Study design and participants for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Procedures for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Statistical analysis for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial